Study treatment and randomization
pre‐dose
Selnoflast (450 mg QD or matching placebo) was administered orally in the morning following an overnight fast of at least 8 h during the patients’ 7‐day clinic stay. Water intake was restricted for 1 h pre‐dose and 1 h post‐dose, and no food was allowed until at least 4 h post‐dose.